Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

Charles M Rudin ,Lisa Guttman,Yixin Ren ,Christy Ralph ,Kevin J Harrington ,Timothy Dudley Clay ,Jonathan E Rosenberg ,Jaime R Merchan ,Steven O’day ,David Campbell ,Gavin Wright ,Brendan D Curti ,Daphne Day ,Emmett V Schmidt ,Hardev Pandha ,Matthew R Zibelman ,Ross Jennens ,Wallace Akerley ,Andrew Hill ,David E Gerber ,Sumati Gupta

doi:10.1136/jitc-2022-005007

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

Charles M Rudin , Lisa Guttman + Show 19 more

Open Access

https://doi.org/10.1136/jitc-2022-005007

Copy DOI

Journal: Journal for ImmunoTherapy of Cancer	Publication Date: Jan 1, 2023
Citations: 4	License type: open-access

#Non-small Cell Lung Cancer #Non-small Cell Lung Cancer Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundOncolytic virus V937 showed activity and safety with intratumoral administration. This phase 1 study evaluated intravenous V937±pembrolizumab in patients with advanced solid tumors.MethodsPatients had advanced non-small cell lung cancer (NSCLC),...

Full Text